AstraZeneca's concurrent Imfinzi-chemo-radiation combo in lung cancer misses primary endpoint in PhIII trial
AstraZeneca’s PD-L1 Imfinzi failed a Phase III trial in non-small cell lung cancer (NSCLC) when investigated concurrently with chemoradiotherapy (CRT) as the company worked to expand the drug’s use from sequential administration and get immunotherapy into patients earlier.
In the PACIFIC-2 trial, Imfinzi and CRT didn’t hit statistical significance for the primary endpoint, progression-free survival, when tested against chemoradiotherapy alone in patients with unresectable, stage 3 NSCLC.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.